AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

 12,172.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 12,370.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.24m
  • Volume: 0
  • Market Cap: £188,695m
  • RiskGrade: 123

ShareCast News

AstraZeneca's Imfinzi plus Imjudo recommended fo... 19-Dec-2022 ShareCast
AstraZeneca's Forziga recommended for EU use 19-Dec-2022 ShareCast
FDA gives AstraZeneca extension on cancer drug a... 15-Dec-2022 ShareCast
AstraZeneca hails positive findings in breast ca... 08-Dec-2022 ShareCast
AstraZeneca sells US manufacturing site 30-Nov-2022 ShareCast
AstraZeneca to buy biotech Neogene for up to $320m 29-Nov-2022 ShareCast
Three AstraZeneca drugs recommended for EU appro... 14-Nov-2022 ShareCast
AstraZeneca's Imfinzi gets FDA approval for lung... 11-Nov-2022 ShareCast
AstraZeneca lifts full-year earnings guidance af... 10-Nov-2022 ShareCast
FDA committee votes in favour of AstraZeneca ast... 09-Nov-2022 ShareCast
Astrazeneca's Beyfortus receives EU approval 04-Nov-2022 ShareCast
AstraZeneca breast cancer drug shows 'significan... 26-Oct-2022 ShareCast
AstraZeneca says Fasenra fails to meet one trial... 25-Oct-2022 ShareCast
AstraZenenca liver cancer combination treatment ... 24-Oct-2022 ShareCast
Japan green lights AstraZeneca asthma drug 27-Sep-2022 ShareCast
AstraZeneca's gMG treatment receives EU approval 23-Sep-2022 ShareCast
AstraZeneca's severe asthma treatment gets EU ap... 21-Sep-2022 ShareCast
AstraZeneca's Covid-19 antibody combination rece... 20-Sep-2022 ShareCast
AstraZeneca blood clot treatment meets trial end... 16-Sep-2022 ShareCast
AstraZeneca, Sanofi respiratory drug gets EU mar... 16-Sep-2022 ShareCast
Credit Suisse upgrades GSK, downgrades AstraZeneca 15-Sep-2022 ShareCast
AstraZeneca's biliary tract cancer treatment rec... 05-Sep-2022 ShareCast
AstraZeneca's Evusheld approved in Japan for tre... 30-Aug-2022 ShareCast
Clinical trials demonstrate that AstraZeneca's F... 30-Aug-2022 ShareCast
ShoreCap stays at 'buy' for Astra Zeneca, citing... 25-Aug-2022 ShareCast
AstraZeneca's Lynparza approved in Japan 25-Aug-2022 ShareCast
Sector movers: Defensives knocking at technical ... 20-Aug-2022 ShareCast
AstraZeneca's prostate cancer drug gets US prior... 16-Aug-2022 ShareCast
AstraZeneca breast cancer drug meets primary and... 15-Aug-2022 ShareCast
AstraZeneca, Daiichi's Enhurtu gets US approval ... 12-Aug-2022 ShareCast
AstraZeneca gets US approval for breast cancer t... 08-Aug-2022 ShareCast
AstraZeneca breast cancer drug receives EU appro... 04-Aug-2022 ShareCast
ShoreCap stays at 'buy' on AstraZeneca, sees fur... 29-Jul-2022 ShareCast
AstraZeneca raises FY revenue guidance, names ne... 29-Jul-2022 ShareCast
Friday preview: US inflation data, AstraZeneca i... 28-Jul-2022 ShareCast
AstraZeneca GMG drug recommended for EU approval 25-Jul-2022 ShareCast
AstraZeneca asthma drug gets EU marketing approval 25-Jul-2022 ShareCast
AstraZeneca breast cancer drug granted priority ... 25-Jul-2022 ShareCast
AstraZeneca breast cancer drug granted priority ... 25-Jul-2022 ShareCast
AstraZeneca's HER2-positive breast cancer drug r... 19-Jul-2022 ShareCast
AstraZeneca agrees to acquire TeneoTwo 05-Jul-2022 ShareCast
Covid-19 cases surge during latest week due to B... 01-Jul-2022 ShareCast
Oxford Biomedica signs new Covid vaccine deal wi... 01-Jul-2022 ShareCast
AstraZeneca receives positive interim results fr... 30-Jun-2022 ShareCast
AstraZeneca's breast cancer drug recommended for... 27-Jun-2022 ShareCast
Citi reiterates 'buy' on AstraZeneca on the back... 22-Jun-2022 ShareCast
AstraZeneca receives 'positive' results from tri... 21-Jun-2022 ShareCast
Berenberg stays at 'buy' for AstraZeneca after t... 06-Jun-2022 ShareCast
AstraZeneca-Daiichi's Enhertu reports positive s... 06-Jun-2022 ShareCast
AstraZeneca autoimmune treatment meets trial end... 05-May-2022 ShareCast

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,172.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 12,370.00
52 Week Low 9,501.00
Volume 0
Shares Issued 1,550.24m
Market Cap £188,695m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.48% below the market average92.48% below the market average92.48% below the market average92.48% below the market average92.48% below the market average
92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average
Price Trend
59.08% above the market average59.08% above the market average59.08% above the market average59.08% above the market average59.08% above the market average
66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average
Income
91.19% below the market average91.19% below the market average91.19% below the market average91.19% below the market average91.19% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
82.60% above the market average82.60% above the market average82.60% above the market average82.60% above the market average82.60% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 8
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page